Why this Dermatologist is Fed Up

Adam Friedman, MD, discusses recent trends in dermatological care and challenges faced by physicians and patients when trying access prescription medications.


Has your health insurer denied your care?

Health insurance companies use various approaches to cut costs.

As a result, your insurer may not cover certain treatments prescribed to you or may require you to take a number of steps before your treatment is approved.

Learn more here

One-third of patients with PsA report barriers to biologic access

Data published in the Journal of Rheumatology revealed that 27% of patients with psoriatic arthritis who had experience with biologics and/or small-molecule agents reported barriers to treatment, with the most common hurdles being coverage ineligibility and high out-of-pocket costs.

Read more

Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies

Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects children and adults. Until recently, the only Food and Drug Administration–approved systemic treatment option for patients with moderate-to-severe AD was systemic steroids, which are not recommended by current guidelines and are commonly associated with disease rebound.

Atopic Dermatitis Quality of Life Report

In 2016/2017 ESC undertook a quality of life insights project to better understand the burden of living with atopic dermatitis, the quality of life impact, and the needs of those living with atopic dermatitis.

Adam Friedman, MD, Elected President of the Derma Care Access Network

From The George Washington University School of Medicine & Health Sciences

The Derma Care Access Network (DCAN) recently elected Adam Friedman, MD, associate professor of dermatology at the George Washington University School of Medicine and Health Sciences, as president of the organization, which advocates for patients who face challenges in getting access to dermatological medications.

DCAN, founded in early 2016, sponsors educational advocacy initiatives and educational programs with the aim of promoting policymaking centered on access to therapies and clinical care in the dermatology field. Stakeholders in the organization include patients, physicians, researchers, and patient advocates; Friedman has been a member since the organization’s inception.

“I am honored to be elected president of this rapidly expanding organization,” Friedman said. “The work DCAN is doing to support patients is incredibly important, and I look forward to advocating for policies that will advance the field of dermatology.”

Friedman said his primary goal is to “advocate for public policy that overcomes barriers limiting patient access to approved treatments and appropriate clinical care for a broad array of skin conditions.”

To accomplish this goal, he said, DCAN will raise awareness about step therapy, prior authorizations, medical switching, and other barriers to access among physicians, members of the industry, policymakers, and patients through educational programming. That programming will include white papers, media engagement, and medical conference engagement, he added.

DCAN is a subgroup of the Alliance for Patient Access, a national network of physicians dedicated to ensuring patient access to approved therapies and appropriate clinical care.

Make Some Noise: Advocating for Access

Adam Friedman, MD, FAAD, is an associate professor of dermatology in the department of dermatology at George Washington School of Medicine and Health Sciences in Washington, DC, where he also serves as the Residency Program Director and the Director of Translational Research. In addition, Dr. Friedman is a member of the medical advisory board for the Derma Care Access Network (DCAN), where he is helping to turn up the volume on important access to care issues in dermatology.


Adam Friedman, MD: DCAN is a project of the Alliance for Patient Access that is dedicated to addressing issues related to access to therapies and clinical care in dermatology. We are a group of stakeholders including patients, patient advocates, physicians, and scientists, and together we are sponsoring educational initiatives and advocacy programs to encourage informed policymaking about the benefits of access to approved therapies and appropriate clinical care.

Read more at Practical Dermatology